The Gallbladder Cancer Therapeutics Market is Forecast to Decline Up to 2018

Wednesday 8 February 2012, Amsterdam

The report is an essential source of information and analysis on the global gallbladder cancer market. The report identifies the key trends shaping and driving the global gallbladder cancer market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global gallbladder cancer sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by a team of industry experts.

The Gallbladder Cancer Therapeutics Market is Forecast to Decline Up to 2018

The analysis estimated the gallbladder cancer therapeutics market to be worth $156.0m in 2010. It is forecast to decline at a Compound Annual Growth Rate (CAGR) of 2.0% for the next eight years to reach $148.68m by 2018. The decline in the gallbladder cancer therapeutics market is primarily due to the patent expiries of Gemzar and Xeloda, which are expected to leave the market vulnerable to generics.

See figure: Gallbladder Cancer Therapeutics Market, Global, Revenue and Forecast ($m), 2005-2018
 

The Gallbladder Cancer Therapeutics Market has Significant Unmet Need

They found that the gallbladder cancer therapeutics market has significant unmet needs. Due to the limited efficacy and safety profiles of the current market products there is considerable scope for new entrants to capture market value. There exists a huge potential for products using new technology with reduced side effects. New drugs entering the market with increased overall survival and safety could capture the market share.   
 
The current products for gallbladder cancer have significant side effect concerns such as alopecia, lethargy, thrombocytopenia and neutropenia. However, many patients are left with no choice other than the current products, which can provide some degree of disease alleviation. Developing new molecular targeted agents should lead to future blockbusters with the potential to capture major market shares. Consequently, there is a huge need for novel drugs to enter the market with benefits over the well-established existing products.

Pipeline Offers No Hope for the Newly Diagnosed Patients

The analysis found that the late stage pipeline lacks targeted therapies to treat newly diagnosed gallbladder cancer patients. As a result, the significant unmet need is anticipated to persist in the near future and the majority of the patients are expected to suffer relapse. With no promising therapies expected in the near future, newly diagnosed patients are left with limited options and have to depend on combination therapies with gemcitabine / cisplatin, oxaliplatin or capecitabine. These chemotherapy regimens provide only symptomatic relief. Hence the gallbladder cancer therapeutics market is underserved.